B2B membership organisation enabling collaboration in biopharmaceuticals

When we were looking for an investment partner to help us go to the next stage of our development, we wanted a passion for the life sciences industry that matched our own. In Vespa Capital we found this

Simon Chalk, co-founder at BioPhorum

Business Profile

BioPhorum is a cross industry collaboration group connecting most of the world's largest biopharmaceutical manufacturers and suppliers to solve pertinent pre-competitive industry challenges and improve operational best practices.

BioPhorum creates an environment where biopharmaceutical companies can collaborate for the benefit of all. This is particularly important given the complexities and high costs involved in manufacturing biopharmaceutical drugs.

BioPhorum facilitates eight forums (“Phorums”) across the biopharmaceutical value chain - Drug Substance, Drug Development, Fill Finish, Technology Roadmap, Supply Partner, Information Technology, MedTech and Cell & Gene Therapy.

Visit BioPhorum

Status: Realised
Exited: May 2021
4yr Revenue CAGR: 20.3%
Sector: Life Sciences

Investment Summary

Vespa Capital exited BioPhorum in May 2021. During our investment, Vespa Capital supported BioPhorum in the development of the management team, including the hiring of a CEO and FD, a re-platform of the IT infrastructure including the financial and reporting systems, as well as strategic expansion into the areas of Cell & Gene Therapy and MedTech and geographic expansion into Asia.

Highly experienced management team, with specialist knowledge and deep relationships in their various fields.
Unique collaboration model, utilising technology to engage with members globally, facilitated by experienced pharmaceutical professionals and industry subject matter experts.
Received recognition in The Sunday Times Fast Track and FT1000 Europe's Fastest Growing Companies 2020.
Enviable levels of deep engagement with a range of companies operating across the biopharmaceutical value chain, including 25 of the 25 largest biopharmaceutical firms.
Members collaborate to drive development at the cutting edge of biopharmaceutical manufacturing.
In 2018 BioPhorum led the production of the Cell & Gene Therapy for the industry and in 2020 incubated a Phorum to focus on MedTech.

What our clients say

When we were looking for an investment partner to help us go to the next stage of our development, we wanted constructive engagement not interference, experience in areas that were new to us and a passion for the life sciences industry that matched our own. In Vespa Capital we found all these things.